ARCH Venture Fund XIII, L.P. (CRANDELL KEITH, GILLIS STEVEN) purchased $25.0M of LYEL (indirect holdings)
ARCH Venture Fund XIII, L.P. purchased 2,321,262 indirectly-held shares of Lyell Immunopharma, Inc. (LYEL) at $10.77 ($25.00M total) on 2026-11-04. Filed jointly with ARCH Venture Partners XIII, L.P. (10% owner), ARCH Venture Partners XIII, LLC (10% owner), CRANDELL KEITH (10% owner), GILLIS STEVEN (10% owner), NELSEN ROBERT (10% owner), Burow Kristina (10% owner), BERNS PAUL L (10% owner) and BYBEE CLINTON (10% owner).
How this was made
The 30-second read
Why it matters
The $25M purchase represents a significant increase in ownership for a micro‑cap biotech, potentially prompting price appreciation.
Market read
Primary insider purchase news with material size; may influence LYEL's short‑term price action.
What to watch
The purchase is indirect; fund may be rebalancing a portfolio rather than signaling company fundamentals.
Background
Form 4 filings disclose insider transactions; large purchases are often viewed as bullish signals.
Ticker impact
ARCH Venture Fund XIII purchased 2.32M shares of LYEL for $25M, increasing its stake to 3.75M shares.
likely upward pressure as the market prices in the insider buying signal
Form 4 filing is a primary source; $25M purchase is material for a micro‑cap biotech and may attract other investors.
Market effects
May boost sentiment toward biotech and specialty pharma sector.
Limited to US markets where LYEL trades.
Minimal global impact beyond LYEL investors.
Counterpoint
Insider buying could be a short‑cover move rather than a long‑term conviction.
Key entities
- CompanyLyell Immunopharma, Inc.
Biotech company developing immunotherapies, ticker LYEL.
- InvestorARCH Venture Fund XIII, L.P.
Venture fund acquiring a 10% stake in LYEL.